Abuse deterrent formulations: Preventing an opioid epidemic
The United States of America is facing a hugely concerning opioid addiction epidemic, causing roughly 46 deaths per day according to the US Centres for Disease Control. This problem has previously been thought of as a uniquely American one due to physicians over-prescribing them, however there is evidence to suggest that this may not be the case. For example, Canada is also facing a large prescription opioid addiction problem, despite its healthcare system being very different to the US one.
The overarching principle underlying all ADF technologies is to prevent abuse without hindering legitimate use.
Christopher Hirst, Head of RPH Pharmaceuticals AB, a subsidiary of Recipharm AB, Damon Smith, chief executive officer of Altus Formulation and Richard Dart, Executive Director of the Researched Abuse, Diversion and Addiction Related Surveillance (RADARS®) System, are featured in Contract Pharma discussing the possibility of a European opioid addiction crisis, and measures that can be put in place to prevent this.
For full article see link: https://www.contractpharma.com/issues/2018-11-01/view_features/abuse-deterrent-formulations-154815/
Discover INTELLITAB™ misuse and abuse deterrent technology.